| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-283
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2004-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca2162202d0215891e888c116772f13e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86efbcca106c7fa6d60bbd52aa2015c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b668c6ca805d1967e4e027e3f0a654a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85acca74b1e8c637cd5b420ec1b023c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe3264b24010b282654dfe9a49431ffb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aa59f62b3b4ebd2e40e0e612ed528ad |
| publicationDate |
2005-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1570858-A1 |
| titleOfInvention |
Monovalent ligand of the FCalphaRi receptor as an anti-inflammatory agent |
| abstract |
The invention relates to the use of anmonovalent antibody fragment directed against the EC2ndomain of the FcαRI receptor for the treatment ofninflammatory diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110577598-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110577598-A |
| priorityDate |
2004-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |